Novel T cell receptor therapy shows early anti-tumor activity



Novel T cell receptor therapy shows early anti-tumor activity

Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial.

Materials provided by University of Texas M. D. Anderson Cancer Center. Note: Content may be edited for style and length.




Source link aaaaa

Related posts

1st June 2023

Open-analysis platform for pediatric brain tumors provides robust data resource for childhood cancer research

Read more
31st May 2023

Plants remove cancer causing toxins from air

Read more
31st May 2023

How the flu virus hacks our cells

Read more